CLDX - Celldex Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.69
-0.17 (-2.96%)
As of 12:11PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close5.86
Open5.86
Bid5.5800 x 1800
Ask5.6200 x 1300
Day's Range5.56 - 6.40
52 Week Range2.70 - 42.90
Volume295,902
Avg. Volume289,114
Market Cap68.81M
Beta (3Y Monthly)4.73
PE Ratio (TTM)N/A
EPS (TTM)-14.8460
Earnings DateMar 5, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.25
Trade prices are not sourced from all markets
  • The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

    The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

  • 5 Tiny Biotech Stocks With Superb Growth Potential
    Zacks6 days ago

    5 Tiny Biotech Stocks With Superb Growth Potential

    A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

  • Benzinga8 days ago

    The Celldex Reverse Stock Split: What Investors Need To Know

    Celldex Therapeutics, Inc. (NASDAQ: CLDX) stock tanked Monday after the company effected a 15-to-1 reverse stock split that was first announced two days ago. The reverse split pushed Celldex’s share price from about 39 cents to about $5 per share, but the market’s negative initial reaction to the decision is typical of the response to reverse splits. Celldex was forced into the aggressive reverse split after the stock crashed 84 percent in the past year as the market lost its optimism about immunotherapy combination treatments.

  • ACCESSWIRE8 days ago

    Biotech Stocks To Watch

    HENDERSON, NV / ACCESSWIRE / February 11, 2019 / Investing in biotech companies can provide investors with huge gains. With that in mind, we're highlighting a few you should know about. One you should ...

  • GlobeNewswire11 days ago

    Celldex Therapeutics Announces Reverse Stock Split

    Celldex Therapeutics, Inc. (CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation. Beginning on February 11, 2019, Celldex’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the new CUSIP number 15117B202. As previously disclosed, at the Company’s Annual Meeting of Stockholders held on June 13, 2018, Celldex stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a ratio of not less than one-for-ten and not more than one-for-fifteen.

  • ACCESSWIRE14 days ago

    4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19)

    CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Moleculin Biotech Inc (MBRX), Celldex Therapeutics Inc (CLDX), and Teladoc Health Inc (TDOC) represent four healthcare companies focused on innovating towards the future of healthcare.

  • ACCESSWIRE14 days ago

    Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...

  • ACCESSWIRE15 days ago

    These 4 Tech Stocks Could Set February Highs

    CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / The future of the tech stock market will depend on two key factors: tech experts must continue to work to design and manufacture top-of-the-line products meant to elevate the human experience, and consumers must feel like these new pieces of tech will actually serve a significant purpose in their lives. ParcelPal Technology Inc (PTNYF) (PKG), Maxwell Technologies Inc (MXWL), Top Image Systems Ltd (TISA), and Celldex Therapeutics Inc (CLDX) represent four companies determined to utilize advanced technological solutions to improve the quality of life for consumers on a global scale. ParcelPal Technology Inc (PTNYF) (PKG), along with other companies in the space, is taking advantage of the fact that, as new technologies have been developed to meet the growing challenges in life, so too has the willingness of consumers to be persuadable, in terms of considering products they otherwise might not consider.

  • ACCESSWIRE21 days ago

    Cannabis and Biotech Stocks that Could Explode

    HENDERSON, NV / ACCESSWIRE / January 29, 2019 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price at ...

  • ACCESSWIRE27 days ago

    Best Ways to Play Biotech Rally

    HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...

  • ACCESSWIRE29 days ago

    A Biotech Play You Can't Afford To Miss

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...

  • Here's Why Celldex Therapeutics Sank on Friday
    Motley Fool2 months ago

    Here's Why Celldex Therapeutics Sank on Friday

    A rotten week for biotech didn't end well for Celldex.

  • Why Celldex Therapeutics Is Jumping Today
    Motley Fool2 months ago

    Why Celldex Therapeutics Is Jumping Today

    There's nothing to get excited about with this clinical-stage biotech stock's double-digit-percentage gain.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss
    Zacks3 months ago

    Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss

    Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.

  • Here's Why Celldex Therapeutics, Inc. Surged on Thursday
    Motley Fool3 months ago

    Here's Why Celldex Therapeutics, Inc. Surged on Thursday

    The company's third-quarter earnings report gave investors lots to look forward to.

  • Celldex Therapeutics Inc. Chugs Along in the 3rd Quarter Despite Challenges
    Motley Fool3 months ago

    Celldex Therapeutics Inc. Chugs Along in the 3rd Quarter Despite Challenges

    The biotech's spending cuts help it preserve cash to fund ongoing clinical studies that are key to its future success.

  • Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates

    Celldex (CLDX) delivered earnings and revenue surprises of 46.67% and -54.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Celldex: 3Q Earnings Snapshot

    On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 4 cents. Losses, adjusted for non-recurring gains, were 8 cents per share. The biopharmaceutical company posted revenue ...

  • Why Shares of Celldex Therapeutics, Inc. Sailed Higher Today
    Motley Fool4 months ago

    Why Shares of Celldex Therapeutics, Inc. Sailed Higher Today

    The clinical-stage biotech received a spark from excitement over the release of abstracts to be presented at a major conference.

  • Why Celldex Therapeutics, Inc. Fell on Monday
    Motley Fool4 months ago

    Why Celldex Therapeutics, Inc. Fell on Monday

    A big loss despite a lack of news for the precommercial biotech.